BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

304 related articles for article (PubMed ID: 24661651)

  • 1. Outcomes of low-risk ductal carcinoma in situ in Southeast Asian women treated with breast conservation therapy.
    Wong FY; Wang F; Chen JJ; Tan CH; Tan PH
    Int J Radiat Oncol Biol Phys; 2014 Apr; 88(5):998-1003. PubMed ID: 24661651
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Factors associated with local recurrence and cause-specific survival in patients with ductal carcinoma in situ of the breast treated with breast-conserving therapy or mastectomy.
    Vargas C; Kestin L; Go N; Krauss D; Chen P; Goldstein N; Martinez A; Vicini FA
    Int J Radiat Oncol Biol Phys; 2005 Dec; 63(5):1514-21. PubMed ID: 16005576
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Can we select individuals with low risk ductal carcinoma in situ (DCIS)? A population-based outcomes analysis.
    Rakovitch E; Nofech-Mozes S; Narod SA; Hanna W; Thiruchelvam D; Saskin R; Taylor C; Tuck A; Sengupta S; Elavathil L; Jani PA; Done SJ; Miller N; Youngson B; Kong I; Paszat L
    Breast Cancer Res Treat; 2013 Apr; 138(2):581-90. PubMed ID: 23456231
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Long-term outcomes of hypofractionation versus conventional radiation therapy after breast-conserving surgery for ductal carcinoma in situ of the breast.
    Lalani N; Paszat L; Sutradhar R; Thiruchelvam D; Nofech-Mozes S; Hanna W; Slodkowska E; Done SJ; Miller N; Youngson B; Tuck A; Sengupta S; Elavathil L; Chang MC; Jani PA; Bonin M; Rakovitch E
    Int J Radiat Oncol Biol Phys; 2014 Dec; 90(5):1017-24. PubMed ID: 25220719
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Improved outcomes of breast-conserving therapy for patients with ductal carcinoma in situ.
    Halasz LM; Sreedhara M; Chen YH; Bellon JR; Punglia RS; Wong JS; Harris JR; Brock JE
    Int J Radiat Oncol Biol Phys; 2012 Mar; 82(4):e581-6. PubMed ID: 22208975
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Hypofractionated radiation therapy for breast ductal carcinoma in situ.
    Hathout L; Hijal T; Théberge V; Fortin B; Vulpe H; Hogue JC; Lambert C; Bahig H; Provencher L; Vavassis P; Yassa M
    Int J Radiat Oncol Biol Phys; 2013 Dec; 87(5):1058-63. PubMed ID: 24113057
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Validation of a nomogram in the prediction of local recurrence risks after conserving surgery for Asian women with ductal carcinoma in situ of the breast.
    Wang F; Li H; Tan PH; Chua ET; Yeo RM; Lim FL; Kim SW; Tan DY; Wong FY
    Clin Oncol (R Coll Radiol); 2014 Nov; 26(11):684-91. PubMed ID: 25194727
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Impact of boost radiation in the treatment of ductal carcinoma in situ: a population-based analysis.
    Rakovitch E; Narod SA; Nofech-Moses S; Hanna W; Thiruchelvam D; Saskin R; Taylor C; Tuck A; Youngson B; Miller N; Done SJ; Sengupta S; Elavathil L; Jani PA; Bonin M; Metcalfe S; Paszat L
    Int J Radiat Oncol Biol Phys; 2013 Jul; 86(3):491-7. PubMed ID: 23708085
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Long-term impact of young age at diagnosis on treatment outcome and patterns of failure in patients with ductal carcinoma in situ treated with breast-conserving therapy.
    Vicini FA; Shaitelman S; Wilkinson JB; Shah C; Ye H; Kestin LL; Goldstein NS; Chen PY; Martinez AA
    Breast J; 2013; 19(4):365-73. PubMed ID: 23815268
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Breast-conserving treatment with or without radiotherapy in ductal carcinoma-in-situ: ten-year results of European Organisation for Research and Treatment of Cancer randomized phase III trial 10853--a study by the EORTC Breast Cancer Cooperative Group and EORTC Radiotherapy Group.
    ; ; Bijker N; Meijnen P; Peterse JL; Bogaerts J; Van Hoorebeeck I; Julien JP; Gennaro M; Rouanet P; Avril A; Fentiman IS; Bartelink H; Rutgers EJ
    J Clin Oncol; 2006 Jul; 24(21):3381-7. PubMed ID: 16801628
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparison of ipsilateral breast tumor recurrence after breast-conserving surgery between ductal carcinoma in situ and invasive breast cancer.
    Choi YJ; Shin YD; Song YJ
    World J Surg Oncol; 2016 Apr; 14():126. PubMed ID: 27122132
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Delay in radiotherapy is associated with an increased risk of disease recurrence in women with ductal carcinoma in situ.
    Shurell E; Olcese C; Patil S; McCormick B; Van Zee KJ; Pilewskie ML
    Cancer; 2018 Jan; 124(1):46-54. PubMed ID: 28960259
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Five year outcome of 145 patients with ductal carcinoma in situ (DCIS) after accelerated breast radiotherapy.
    Ciervide R; Dhage S; Guth A; Shapiro RL; Axelrod DM; Roses DF; Formenti SC
    Int J Radiat Oncol Biol Phys; 2012 Jun; 83(2):e159-64. PubMed ID: 22579378
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Should ductal carcinoma-in-situ (DCIS) be removed from the ASTRO consensus panel cautionary group for off-protocol use of accelerated partial breast irradiation (APBI)? A pooled analysis of outcomes for 300 patients with DCIS treated with APBI.
    Vicini F; Shah C; Ben Wilkinson J; Keisch M; Beitsch P; Lyden M
    Ann Surg Oncol; 2013 Apr; 20(4):1275-81. PubMed ID: 23054123
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effect of margins on ipsilateral breast tumor recurrence after breast conservation therapy for lymph node-negative breast carcinoma.
    Leong C; Boyages J; Jayasinghe UW; Bilous M; Ung O; Chua B; Salisbury E; Wong AY
    Cancer; 2004 May; 100(9):1823-32. PubMed ID: 15112262
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prospective multicenter trial evaluating balloon-catheter partial-breast irradiation for ductal carcinoma in situ.
    Abbott AM; Portschy PR; Lee C; Le CT; Han LK; Washington T; Kinney M; Bretzke M; Tuttle TM
    Int J Radiat Oncol Biol Phys; 2013 Nov; 87(3):494-8. PubMed ID: 24074922
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Radiation treatment for ductal carcinoma in situ (DCIS): is a boost to the tumor bed necessary?
    Yerushalmi R; Sulkes A; Mishaeli M; Neumann A; Dinerman M; Sulkes J; Rizel S; Yarom N; Gutman H; Fenig E
    Neoplasma; 2006; 53(6):507-10. PubMed ID: 17167720
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Combined surgery and radiotherapy in the treatment of ductal carcinoma in situ of the breast: preliminary results of the Hungarian multicenter prospective randomised study].
    Polgár C; Orosz Z; Kahán Z; Gábor G; Jani N; Cserni G; Hadijev J; Kulka J; Sulyok Z; Boross G; Lázár G; László Z; Diczházi C; Udvarhelyi N; Szabó E; Péntek Z; Major T; Fodor J
    Magy Onkol; 2008 Sep; 52(3):269-77. PubMed ID: 18845497
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Ductal carcinoma in situ--the influence of the radiotherapy boost on local control.
    Wong P; Lambert C; Agnihotram RV; David M; Duclos M; Freeman CR
    Int J Radiat Oncol Biol Phys; 2012 Feb; 82(2):e153-8. PubMed ID: 21664063
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Defining negative margins in DCIS patients treated with breast conservation therapy: The University of Chicago experience.
    Sahoo S; Recant WM; Jaskowiak N; Tong L; Heimann R
    Breast J; 2005; 11(4):242-7. PubMed ID: 15982389
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.